期刊文献+

结肠癌术后辅助化疗患者远期生存状况和预后危险因素分析 被引量:7

Analysis of long-term survival status and prognostic risk factors of postoperative adjuvant chemotherapy in patients with colon cancer
下载PDF
导出
摘要 目的探究结肠癌术后辅助化疗患者的远期生存状况及其预后危险因素。方法回顾性分析2013年2月至2014年2月于青岛市市立医院行术后辅助化疗的98例结肠癌患者的临床资料,记录患者化疗相关不良反应发生情况及其生存状况,采用Kaplan-Meier生存曲线分析患者5年生存率,采用多因素Logistic回归分析影响结肠癌术后辅助化疗患者预后的危险因素。结果98例患者均顺利完成化疗,其不良反应主要以中性粒细胞减少(78例)和恶心呕吐(59例)居多,其次为口腔黏膜炎(26例)、手足麻木(18例)、腹泻(17例)、血小板减少(10例),均为Ⅰ~Ⅱ级,未影响治疗。随访5年,98例结肠癌患者1、3、5年生存率分别为87.76%、71.43%、62.24%。死亡组和存活组患者美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)评分、组织分化程度、淋巴结转移数目、脉管侵犯情况、临床分期及术前癌胚抗原(carcinoembryonic antigen,CEA)水平比较差异均具有统计学意义(均P<0.05)。多因素Logistic回归分析结果显示:组织分化程度低、淋巴结转移数目≥4个、临床分期Ⅲ期及术前CEA水平≥5μg/L是影响结肠癌术后辅助化疗患者预后的独立危险因素(均P<0.05)。结论结肠癌术后辅助化疗患者5年生存率为62.24%,组织分化程度低、淋巴结转移数目≥4个、临床分期Ⅲ期及术前CEA水平≥5μg/L是影响结肠癌术后辅助化疗患者预后的独立危险因素。 Objective To investigate the long-term survival status and prognostic risk factors of postoperative adjuvant chemotherapy in patients with colon cancer.Method The clinical data of 98 patients with colon cancer who received postoperative adjuvant chemotherapy in Qingdao Municipal Hospital from February 2013 to February 2014 were analyzed retrospectively,and the occurrence and survival status of chemotherapy-related adverse reactions were recorded,Kaplan-Meier survival curve was used to analyze the 5-year survival rate,and multivariate Logistic regression was used to analyze the risk factors affecting the prognosis of patients with colon cancer after adjuvant chemotherapy.Result All the 98 patients completed chemotherapy successfully.The main adverse reactions were neutropenia(78 cases)and nausea and vomiting(59 cases),this was followed by oral mucositis(26 cases),hand and foot numbness(18 cases),diarrhea(17 cases)and thrombocytopenia(10 cases),all of which were gradeⅠ~Ⅱand did not affect the treatment.During the 5-year follow-up,the 1-,3-and 5-year survival rates of 98 patients with colon cancer were 87.76%,71.43%and 62.24%,respectively.There were significant differences in Eastern Cooperative Oncology Group(ECOG)score,tissue differentiation,number of lymph node metastasis,vascular invasion,clinical stage and preoperative carcinoembryonic antigen(CEA)level between death group and survival group(all P<0.05).The results of multivariate Logistic regression analysis showed that low tissue differentiation,more than 4 lymph node metastases,clinical stageⅢand preoperative CEA level≥5μg/L were independent risk factors affecting the prognosis of postoperative adjuvant chemotherapy patients with colon cancer.Conclusion The 5-year survival rate of patients with postoperative adjuvant chemotherapy for colon cancer was 62.24%.Low degree of tissue differentiation,more than 4 lymph node metastases,clinical stageⅢand preoperative CEA level≥5μg/L were independent risk factors affecting the prognosis of patients with postoperative adjuvant chemotherapy.
作者 梁忆波 季涛 崔琳 Liang Yibo;Ji Tao;Cui Lin(Department of Colorectal Surgery,Qingdao Municipal Hospital,Shandong,Qingdao 266011,China;Department of Radiology,Qingdao Municipal Hospital,Shandong,Qingdao 266011,China;Pathology Laboratory,Qingdao Municipal Hospital,Shandong,Qingdao 266011,China)
出处 《中国医学前沿杂志(电子版)》 2020年第10期137-140,共4页 Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词 结肠癌 辅助化疗 远期生存 预后 危险因素 Colon cancer Adjuvant chemotherapy Long-term survival Prognosis Risk factor
  • 相关文献

参考文献12

二级参考文献114

  • 1张思维,雷正龙,李光琳,邹小农,陈万青,赵平.中国肿瘤登记地区2005年发病死亡资料分析[J].中国肿瘤,2009,18(12):973-979. 被引量:32
  • 2黄少军,汪晶晶,江华,曹红亮.结肠癌组织中miR-155表达在预测复发转移中的价值及其与血清CEA的相关性[J].肿瘤防治研究,2014,41(6):606-609. 被引量:3
  • 3张思维,陈万青,孔灵芝,李连弟,鲁凤珠,李光琳,孟佳,赵平.中国部分市县1998~2002年恶性肿瘤的发病与死亡[J].中国肿瘤,2006,15(7):430-448. 被引量:171
  • 4朱美英,朱云,计凤妹.上海市松江区大肠癌发病状况及趋势分析[J].上海预防医学,2007,19(9):429-431. 被引量:8
  • 5Muss HB, Bynum DL. Adjuvant chemotherapy in older patients with stage Ill colon cancer: an underused lifesaving treatment [J]. J Clin Oncol, 2012, 30 ( 21 ): 2576-2578. IX)h 10. 1200/ JCO. 2012.42. 3780.
  • 6Reese ES,Onukwugha E, Hanna N, et al. Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients [J]. Cancer Med,2013,2(6) :907-915. IX)l: 10. 1002/cam4. 143.
  • 7Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes" B and C carcinoma of the colon- results from National Surgical Adjuvant Breast and Bowel Project C-04 [J]. J Clin Oncol, 1999,17(11) : 3553-3559.
  • 8Haller DG, Catalano PJ, Macdonald JS, et al. Phase IU study of fluorouracil, leucovorin, and levamisole in high-risk stage I][ and colon cancer: final report of Intergroup 0089 [J]. J Clin Oncol, 2005,23 (34) : 8671-8678. DOI: 10. 1200/JCO. 2004.00. 5686.
  • 9Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage [ or I]1 colon cancer in the MOSAIC trial[J]. J Clin Oncol, 2009, 27 ( 19 ): 3109-3116. DOI: 10. 1200/ JCO. 2008.20. 6771.
  • 10Yothers G, O'Connell M J, Allegra C J, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses[J]. J Clin Onco[,2011, 29 ( 28 ): 3768-3774. IX)l: 10. 1200/ JCO. 2011.36.4539.

共引文献850

同被引文献87

引证文献7

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部